|
|
- 2016
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's diseaseDOI: 10.1016/j.trci.2016.06.002 Keywords: Alzheimer's disease, Monoclonal antibody, Clinical trial, Pharmacokinetics, Adverse events Abstract: Aducanumab (BIIB037), a human monoclonal antibody selective for aggregated forms of amyloid beta, is being investigated as a disease-modifying treatment for Alzheimer's disease (AD)
|
